Dr. Sabha Ganai is a respected Chicago surgical oncologist who has overseen multidisciplinary management of tumors spanning the hepatobiliary system, stomach, and foregut. In the latter area, Dr. Sabha Ganai has experience treating cancer of the esophagus and pancreas.
Each year 55,000 Americans are diagnosed with pancreatic cancer, which centers on an organ tasked with secreting hormones that regulate blood sugar levels, as well as enzymes that assist in digestion. Involving mutated pancreatic cells, the condition is particularly threatening due to the way it quickly spreads to nearby organs.
Researchers at Tel Aviv University recently completed studies that demonstrate the effectiveness of the small molecule PJ34 in inducing self-destruction in pancreatic cancer cells. The mechanism of this molecule, which safely results in cancer cell self-destruction during the mitosis, or duplication, stage, was first published in 2017.
The latest studies involved xenografts, or the transplantation of human pancreatic cancer within immunocompromised mice. The results were that cancer cells within developed tumors were decreased by 90 percent within a single month after drug administration. Adverse effects were not observed, with no behavioral or weight gain changes occurring in the mice.
A former assistant professor for Southern Illinois University,
University of Chicago fellow and surgical oncologist